Full-Time

Associate IS Engineer

Clinical Trial Registry System

Posted on 11/1/2025

Amgen

Amgen

10,001+ employees

Biotech company creating biologic medicines

No salary listed

Hyderabad, Telangana, India

In Person

Category
Data & Analytics (3)
, ,
Required Skills
Agile
Python
JIRA
SCRUM
REST APIs
Confluence
Databricks
Requirements
  • Bachelor’s degree and 2 to 6 years of relevant experience
  • Must-Have Skills: Ability to analyze and interpret complex data to identify and remediate issues
  • Must-Have Skills: Sharp learning agility, problem-solving and analytical thinking
  • Must-Have Skills: Scripting skills such as PowerShell or Python
  • Must-Have Skills: Strong knowledge of Data Lake technologies like Databricks, etc.
  • Must-Have Skills: Experience in MuleSoft, Python script and REST/RESTful API script development.
  • Must-Have Skills: Experience in Clinical system integration.
  • Must-Have Skills: Good written and verbal communication skills
  • Must-Have Skills: Experience working in agile methodology, including Product Teams and Product Development models leading Scrum teams using Jira and Confluence, and adopting Agile methodologies like Kanban and Lean for product development.
  • Must-Have Skills: Proficiency in designing scalable, secure, and cost-effective solutions like cost optimization using AWS Cost Explorer.
  • Must-Have Skills: Have stakeholder and team management skills.
  • Must-Have Skills: Could lead and guide multiple teams to meet business needs and goals.
Responsibilities
  • Collaborate with business and data stakeholders to gather requirements, assess data needs, and ensure data quality, privacy, and compliance across ETL pipelines.
  • Develop, monitor, and maintain CI/ CD-enabled ETL pipelines using Databricks and AWS services (S3, Glue, Lambda, EMR, etc.).
  • Optimize ETL jobs for performance, scalability, cost-efficiency, and data quality using standard processes for data ingestion, transformation, and loading.
  • Identify, fix, and resolve pipeline bottlenecks or failures to maintain data pipeline health.
  • Maintain user documentation for data definitions, flows, lineage, and quality rules to support audit readiness and data governance.
  • Ensure alignment to data governance policies and contribute to improvement initiatives around data standardization and harmonization.
  • Engage in Agile/SAFe ceremonies, provide story estimates, and deliver user stories related to data platform enhancements.
  • Participate in sprint planning meetings and provide estimations on technical implementation
  • Work with data engineers on data quality assessment, data cleansing and data analytics.
  • Share and discuss findings with team members practicing SAFe Agile delivery model.
  • Automate and Optimize data pipeline and framework for easier and cost-effective development process.
  • Assist in driving validation and compliance readiness by overseeing the development of validation plans, IQ/OQ/PQ protocols, and related documentation as per GXP, 21 CFR Part 11, and Annex 11 guidelines.
  • Oversee user access controls, role-based privileges, and audit trail configurations to ensure system integrity and security are maintained.
  • Support the change control process for the submission system by aligning with ITIL standards and ensuring traceability for all updates, patches, and configuration changes.
  • Use Jira and ServiceNow for project tracking, issue resolution, and service management.
Desired Qualifications
  • Experience with IS Security
  • Experience with Agile Project Methodology
  • Familiarity with cloud platforms (e.g., AWS, Azure, Google Cloud) and their IAM services.
  • Knowledge of IGA principles, including role-based access control (RBAC)
  • Knowledge of incident response procedures and the ability to manage security incidents related to identity management
  • Microsoft, GCP or AWS Cloud (preferred)
  • Security Certification (preferred)
  • Microsoft Azure Certification (preferred)
  • Analytical and troubleshooting skills
  • Good verbal and written communication skills
  • Ability to work effectively with global, virtual teams
  • High degree of initiative and self-motivation
  • Ability to manage multiple priorities successfully
  • Team oriented, with a focus on achieving team goals

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Simplify Jobs

Simplify's Take

What believers are saying

  • Tarlatamab wins China NMPA approval May 2026 for $2B+ sales potential.
  • Q1 2026 revenues hit $8.6B with 16 brands posting double-digit growth.
  • Zai Lab partners on DLL3-ADC plus IMDELLTRA for SCLC trials.

What critics are saying

  • Prolia sales drop 34% to $727M from biosimilar competition in Q1 2026.
  • FDA warns Tavneos causes liver injuries, proposes approval withdrawal.
  • Horizon drugs Tepezza, Uplizna, Krystexxa underperform 19 months post-acquisition.

What makes Amgen unique

  • Amgen's BiTE platform establishes IMDELLTRA as second-line SCLC standard.
  • MariTide advances in Phase III obesity trials with monthly dosing.
  • UPLIZNA surges 73% post-IgG4 and gMG approvals in 2025.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Apr 10th, 2026
Amgen's lung cancer drug tarlatamab wins China approval, seen as $2B+ opportunity

Amgen's lung cancer drug tarlatamab has received approval from China's National Medical Products Administration, according to its development partner BeOne Medicines. The drug is a targeted immunotherapy for adults with extensive-stage small cell lung cancer that has progressed despite chemotherapy. Sold as Imdelltra in the US, tarlatamab is a bispecific antibody designed to connect cancer cells with immune cells, enabling the body's immune system to destroy the cancer. Neither Amgen nor Hong Kong-listed BeOne provided details on launch date or pricing for the Chinese market. Wall Street analysts estimate tarlatamab could generate annual sales exceeding $2 billion for Amgen.

Yahoo Finance
Apr 3rd, 2026
Amgen faces Tavneos liver injury warning as Zai Lab oncology collaboration expands IMDELLTRA pipeline

Amgen faces fresh safety concerns after the FDA warned of severe liver injuries, including vanishing bile duct syndrome, linked to Tavneos (avacopan) in late March 2026. The development adds regulatory risk to the company's investment profile. Separately, Zai Lab announced a global collaboration with Amgen to test its DLL3-targeting ADC alongside Amgen's IMDELLTRA in extensive-stage small cell lung cancer, underscoring the company's ongoing oncology expansion through external partnerships. Amgen's narrative projects $37.4 billion revenue and $8.2 billion earnings by 2028, requiring 2.3% yearly revenue growth. However, pessimistic analysts model revenues slipping to $34.4 billion with earnings near $5.2 billion, reflecting concerns around pricing pressure, biosimilar competition and rising research and development spend alongside the new safety issues.

Yahoo Finance
Mar 30th, 2026
Amgen stock up 24% since Jim Cramer's June recommendation, beats earnings estimates

Amgen, one of the world's largest pharmaceutical companies, has seen its shares rise 24% since Jim Cramer discussed the stock on Mad Money in June 2025. The company is currently developing the weight loss drug MariTide. Amgen's shares jumped 7.5% in November 2025 after posting third-quarter results that beat analyst expectations, with $9.6 billion in revenue and $5.64 earnings per share against forecasts of $8.98 billion and $5.04 respectively. In February 2026, shares rose 8% following fourth-quarter earnings that also exceeded estimates. Cramer expressed cautious optimism about the biotech company, noting its mid-single-digit earnings growth and potential upside from its GLP-1 drug development. Whilst calling Eli Lilly his preferred GLP-1 play, Cramer said investors "could do a lot worse than Amgen" for a bargain option.

Yahoo Finance
Mar 25th, 2026
Wells Fargo lifts Amgen price target to $390, cites $20B myasthenia gravis market potential by 2036

Wells Fargo has raised its price target on Amgen to $390 from $375, maintaining an Equal Weight rating. The firm cited emerging therapies including CD20, BAFF/APRIL and next-generation complement inhibitors as potential drivers that could expand the generalized myasthenia gravis market threefold over the next decade, potentially reaching $15 billion in US sales and $20 billion globally by 2036. Separately, Jefferies initiated coverage on Amgen with a Hold rating and $350 price target on 10 March, noting the stock has gained approximately 35% over the past six months. Last month, Amgen reported fourth-quarter adjusted earnings per share of $5.29, beating the $4.76 consensus estimate, on revenue of $9.9 billion versus $9.45 billion expected.

Yahoo Finance
Mar 15th, 2026
Amgen joins TrumpRx discount scheme and lifts dividend to $2.52 per share

Amgen has announced a $2.52 per-share second-quarter dividend and joined the government-run TrumpRx platform to offer discounted drugs including Amjevita, Aimovig and Repatha. The company is also preparing for its 11 March presentation at the Leerink Global Healthcare Conference in Miami. The moves come alongside double-digit revenue and earnings per share growth in 2025 and advances in obesity and oncology programmes. However, the TrumpRx discounting could pressure net pricing as Amgen invests heavily in late-stage trials and manufacturing expansion. Amgen's narrative projects $37.4 billion revenue and $8.2 billion earnings by 2028, requiring 2.3% yearly revenue growth. Some analysts see a tougher outlook, with revenue potentially drifting towards $34.4 billion and earnings around $5.2 billion.

INACTIVE